NASDAQ:FLKS - Flex Pharma Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$0.4020 -0.01 (-2.43 %)
(As of 12/16/2018 07:18 AM ET)
Previous Close$0.4020
Today's Range$0.40 - $0.4297
52-Week Range$0.38 - $8.98
Volume341,027 shs
Average Volume584,206 shs
Market Capitalization$7.26 million
P/E RatioN/A
Dividend YieldN/A
Flex Pharma, Inc. operates as a biotechnology company. It engages in developing treatments for exercise-associated muscle cramps, nocturnal leg cramps and spasms associated with severe neuromuscular conditions. The company operates through the following business segments: Consumer Operations and Drug Development. The Consumer Operations segment includes HOTSHOT product and consumer operations. The Drug Development segment engages in the development of innovative and proprietary drug products to treat muscle cramps and spasms associated with severe neurological conditions. Flex Pharma was founded by Christoph Westphal and Jennifer M. Cermak on February 26, 2014 and is headquartered in Boston, MA.

Receive FLKS News and Ratings via Email

Sign-up to receive the latest news and ratings for FLKS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Current SymbolNASDAQ:FLKS
Previous Symbol


Debt-to-Equity RatioN/A
Current Ratio4.75
Quick Ratio4.67


Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$1.27 million
Price / Sales5.72
Cash FlowN/A
Price / Cash FlowN/A
Book Value$1.62 per share
Price / Book0.25


EPS (Most Recent Fiscal Year)($1.99)
Net Income$-34,430,000.00
Net Margins-2,919.75%
Return on Equity-148.15%
Return on Assets-121.28%


Outstanding Shares18,070,000
Market Cap$7.26 million

Flex Pharma (NASDAQ:FLKS) Frequently Asked Questions

What is Flex Pharma's stock symbol?

Flex Pharma trades on the NASDAQ under the ticker symbol "FLKS."

How were Flex Pharma's earnings last quarter?

Flex Pharma Inc (NASDAQ:FLKS) issued its earnings results on Monday, November, 5th. The biotechnology company reported ($0.15) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.21) by $0.06. The biotechnology company earned $0.25 million during the quarter. Flex Pharma had a negative return on equity of 148.15% and a negative net margin of 2,919.75%. View Flex Pharma's Earnings History.

When is Flex Pharma's next earnings date?

Flex Pharma is scheduled to release their next quarterly earnings announcement on Wednesday, March 6th 2019. View Earnings Estimates for Flex Pharma.

What price target have analysts set for FLKS?

5 analysts have issued 12 month price objectives for Flex Pharma's stock. Their forecasts range from $6.00 to $40.00. On average, they expect Flex Pharma's stock price to reach $17.50 in the next year. This suggests a possible upside of 4,253.2% from the stock's current price. View Analyst Price Targets for Flex Pharma.

What is the consensus analysts' recommendation for Flex Pharma?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Flex Pharma in the last year. There are currently 3 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Flex Pharma.

What are Wall Street analysts saying about Flex Pharma stock?

Here are some recent quotes from research analysts about Flex Pharma stock:
  • 1. According to Zacks Investment Research, "Flex Pharma, Inc. is a biotechnology company. The Company is involved in developing treatments for nocturnal leg cramps and spasms associated with severe neuromuscular conditions. Flex Pharma, Inc. is headquartered in Boston, Massachusetts. " (9/21/2018)
  • 2. Cantor Fitzgerald analysts commented, "Exploratory Phase II study of FLX-787 in MS showed statistically significant reduction of 27.3% (p=0.001) in frequency of cramps and a 1.4-day increase in the number of cramp-free days (p=0.0457)." (3/27/2018)

Has Flex Pharma been receiving favorable news coverage?

Press coverage about FLKS stock has trended somewhat positive recently, InfoTrie Sentiment Analysis reports. The research group rates the sentiment of press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Flex Pharma earned a news impact score of 1.0 on InfoTrie's scale. They also assigned news coverage about the biotechnology company a news buzz of 4.0 out of 10, indicating that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the next few days.

Are investors shorting Flex Pharma?

Flex Pharma saw a increase in short interest in the month of November. As of November 15th, there was short interest totalling 1,084,264 shares, an increase of 42.9% from the October 31st total of 758,840 shares. Based on an average daily volume of 1,418,761 shares, the short-interest ratio is presently 0.8 days. Currently, 8.1% of the shares of the stock are sold short. View Flex Pharma's Current Options Chain.

Who are some of Flex Pharma's key competitors?

Who are Flex Pharma's key executives?

Flex Pharma's management team includes the folowing people:
  • William K. McVicar, President, Chief Executive Officer & Director
  • John McCabe, Chief Financial Officer, Secretary & Treasurer
  • Elizabeth Woo, SVP-Investor Relations & Corporate Communications

When did Flex Pharma IPO?

(FLKS) raised $60 million in an IPO on Thursday, January 29th 2015. The company issued 4,600,000 shares at $12.00-$14.00 per share. Jefferies and Piper Jaffray served as the underwriters for the IPO and JMP Securities, Cantor Fitzgerald and Roth Capital Partners were co-managers.

Who are Flex Pharma's major shareholders?

Flex Pharma's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Renaissance Technologies LLC (3.94%) and Vanguard Group Inc (1.27%). View Institutional Ownership Trends for Flex Pharma.

Which institutional investors are selling Flex Pharma stock?

FLKS stock was sold by a variety of institutional investors in the last quarter, including Vanguard Group Inc. View Insider Buying and Selling for Flex Pharma.

Which institutional investors are buying Flex Pharma stock?

FLKS stock was purchased by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC. View Insider Buying and Selling for Flex Pharma.

How do I buy shares of Flex Pharma?

Shares of FLKS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Flex Pharma's stock price today?

One share of FLKS stock can currently be purchased for approximately $0.4020.

How big of a company is Flex Pharma?

Flex Pharma has a market capitalization of $7.26 million and generates $1.27 million in revenue each year. The biotechnology company earns $-34,430,000.00 in net income (profit) each year or ($1.99) on an earnings per share basis. Flex Pharma employs 22 workers across the globe.

What is Flex Pharma's official website?

The official website for Flex Pharma is

How can I contact Flex Pharma?

Flex Pharma's mailing address is 800 Boylston Street 24th Floor, Boston MA, 02199. The biotechnology company can be reached via phone at 617-874-1821 or via email at [email protected]

MarketBeat Community Rating for Flex Pharma (NASDAQ FLKS)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  289 (Vote Outperform)
Underperform Votes:  209 (Vote Underperform)
Total Votes:  498
MarketBeat's community ratings are surveys of what our community members think about Flex Pharma and other stocks. Vote "Outperform" if you believe FLKS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe FLKS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/16/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.

Yahoo Gemini Pixel